vs
Lantheus Holdings, Inc.（LNTH）とUiPath, Inc.（PATH）の財務データ比較。上の社名をクリックして会社を切り替えられます
UiPath, Inc.の直近四半期売上が大きい（$411.1M vs $406.8M、Lantheus Holdings, Inc.の約1.0倍）。UiPath, Inc.の純利益率が高く（48.4% vs 13.3%、差は35.1%）。UiPath, Inc.の前年同期比売上増加率が高い（15.9% vs 4.0%）。Lantheus Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$81.4M vs $25.1M）。過去8四半期でLantheus Holdings, Inc.の売上複合成長率が高い（4.9% vs 0.7%）
ランティウス・ホールディングスはグローバルな医療企業で、革新的な診断用造影剤や関連ソリューションの開発・製造・販売を事業の核としています。製品は腫瘍学、循環器学、泌尿器学などの分野に対応し、北米を中心に世界の主要市場で事業を展開しています。
UiPath Inc.は人工知能（AI）、自律型オートメーションおよびオーケストレーションソフトウェアを開発するグローバルソフトウェア企業です。同社の製品は複雑な業務プロセスやワークフローを自動化するAIエージェントの構築・管理に対応し、各業界の業務効率向上を支援しています。
LNTH vs PATH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $406.8M | $411.1M |
| 純利益 | $54.1M | $198.8M |
| 粗利率 | 59.2% | 83.3% |
| 営業利益率 | 19.0% | 3.2% |
| 純利益率 | 13.3% | 48.4% |
| 売上前年比 | 4.0% | 15.9% |
| 純利益前年比 | 558.8% | 1966.2% |
| EPS（希薄化後） | $0.86 | $0.37 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $406.8M | $411.1M | ||
| Q3 25 | $384.0M | $361.7M | ||
| Q2 25 | $378.0M | $356.6M | ||
| Q1 25 | $372.8M | $423.6M | ||
| Q4 24 | $391.1M | $354.7M | ||
| Q3 24 | $378.7M | $316.3M | ||
| Q2 24 | $394.1M | $335.1M | ||
| Q1 24 | $370.0M | $405.3M |
| Q4 25 | $54.1M | $198.8M | ||
| Q3 25 | $27.8M | $1.6M | ||
| Q2 25 | $78.8M | $-22.6M | ||
| Q1 25 | $72.9M | $51.8M | ||
| Q4 24 | $-11.8M | $-10.7M | ||
| Q3 24 | $131.1M | $-86.1M | ||
| Q2 24 | $62.1M | $-28.7M | ||
| Q1 24 | $131.1M | $33.9M |
| Q4 25 | 59.2% | 83.3% | ||
| Q3 25 | 57.9% | 82.2% | ||
| Q2 25 | 63.8% | 82.1% | ||
| Q1 25 | 63.8% | 84.8% | ||
| Q4 24 | 63.5% | 82.0% | ||
| Q3 24 | 63.9% | 80.0% | ||
| Q2 24 | 64.9% | 83.5% | ||
| Q1 24 | 65.4% | 86.8% |
| Q4 25 | 19.0% | 3.2% | ||
| Q3 25 | 11.4% | -5.6% | ||
| Q2 25 | 23.3% | -4.6% | ||
| Q1 25 | 27.4% | 7.9% | ||
| Q4 24 | 29.1% | -12.2% | ||
| Q3 24 | 35.3% | -32.7% | ||
| Q2 24 | 26.1% | -14.8% | ||
| Q1 24 | 28.8% | 3.7% |
| Q4 25 | 13.3% | 48.4% | ||
| Q3 25 | 7.2% | 0.4% | ||
| Q2 25 | 20.8% | -6.3% | ||
| Q1 25 | 19.6% | 12.2% | ||
| Q4 24 | -3.0% | -3.0% | ||
| Q3 24 | 34.6% | -27.2% | ||
| Q2 24 | 15.8% | -8.6% | ||
| Q1 24 | 35.4% | 8.4% |
| Q4 25 | $0.86 | $0.37 | ||
| Q3 25 | $0.41 | $0.00 | ||
| Q2 25 | $1.12 | $-0.04 | ||
| Q1 25 | $1.02 | $0.09 | ||
| Q4 24 | $-0.18 | $-0.02 | ||
| Q3 24 | $1.79 | $-0.15 | ||
| Q2 24 | $0.88 | $-0.05 | ||
| Q1 24 | $1.87 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $359.1M | $1.4B |
| 総負債低いほど良い | $568.7M | — |
| 株主資本純資産 | $1.1B | $1.9B |
| 総資産 | $2.2B | $2.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.52× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $359.1M | $1.4B | ||
| Q3 25 | $382.0M | $1.4B | ||
| Q2 25 | $695.6M | $1.6B | ||
| Q1 25 | $938.5M | $1.6B | ||
| Q4 24 | $912.8M | $1.6B | ||
| Q3 24 | $866.4M | $1.7B | ||
| Q2 24 | $757.0M | $1.9B | ||
| Q1 24 | $718.3M | $1.9B |
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.2B | $1.8B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | $1.0B | $2.0B | ||
| Q1 24 | $945.5M | $2.0B |
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.3B | $2.6B | ||
| Q2 25 | $2.1B | $2.6B | ||
| Q1 25 | $2.1B | $2.9B | ||
| Q4 24 | $2.0B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $1.9B | $2.8B | ||
| Q1 24 | $1.8B | $3.0B |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $90.2M | $28.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $81.4M | $25.1M |
| FCFマージンFCF / 売上 | 20.0% | 6.1% |
| 設備投資強度設備投資 / 売上 | 2.2% | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 1.67× | 0.14× |
| 直近12ヶ月FCF直近4四半期 | $354.1M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $90.2M | $28.3M | ||
| Q3 25 | $105.3M | $41.6M | ||
| Q2 25 | $87.1M | $119.0M | ||
| Q1 25 | $107.6M | $146.1M | ||
| Q4 24 | $157.7M | $28.1M | ||
| Q3 24 | $175.1M | $46.4M | ||
| Q2 24 | $84.7M | $100.0M | ||
| Q1 24 | $127.2M | $145.6M |
| Q4 25 | $81.4M | $25.1M | ||
| Q3 25 | $94.7M | — | ||
| Q2 25 | $79.1M | $106.2M | ||
| Q1 25 | $98.8M | $138.7M | ||
| Q4 24 | $141.4M | $23.2M | ||
| Q3 24 | $159.3M | $45.0M | ||
| Q2 24 | $73.5M | $98.8M | ||
| Q1 24 | $119.0M | $141.8M |
| Q4 25 | 20.0% | 6.1% | ||
| Q3 25 | 24.7% | — | ||
| Q2 25 | 20.9% | 29.8% | ||
| Q1 25 | 26.5% | 32.7% | ||
| Q4 24 | 36.1% | 6.5% | ||
| Q3 24 | 42.0% | 14.2% | ||
| Q2 24 | 18.7% | 29.5% | ||
| Q1 24 | 32.2% | 35.0% |
| Q4 25 | 2.2% | 0.8% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 2.1% | 3.6% | ||
| Q1 25 | 2.3% | 1.7% | ||
| Q4 24 | 4.2% | 1.4% | ||
| Q3 24 | 4.2% | 0.4% | ||
| Q2 24 | 2.8% | 0.4% | ||
| Q1 24 | 2.2% | 0.9% |
| Q4 25 | 1.67× | 0.14× | ||
| Q3 25 | 3.79× | 26.25× | ||
| Q2 25 | 1.11× | — | ||
| Q1 25 | 1.47× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.97× | 4.29× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
